Immune checkpoint inhibitors (ICIs) are a novel class of immunotherapy drugs that have
improved the treatment of a broad spectrum of cancers as metastatic melanoma, non-small …

Immunologic control of malignancy has long been recognized as an important determinant
of disease progression. Recent advances in immunology have led to the focus on several …

Renal toxicities have been increasingly recognized as complications of the immune
checkpoint inhibitors (ICIs). Recent studies have outlined the incidence and potential risk …

Abstract Background/objectives Acute Kidney Injury (AKI), induced by Checkpoint Inhibitors
therapies (CPI-induced AKI), is an uncommon but severe Immune-Related Adverse Event …

Since their introduction into clinical practice a decade ago, immune checkpoint inhibitors
(ICIs) have had an overwhelming impact on cancer treatment. Use of these agents in …

Immune checkpoint inhibitors have been approved for a variety of cancer species. Renal
complications in use of these agents are not very common compared with other immune …

Immune checkpoint inhibitors (ICPIs) have transformed the landscape of oncology, but are
associated with a variety of autoimmune adverse events, including AKI. ICPI-associated AKI …

The development of immune checkpoint inhibitors (ICIs) has driven a revolutionary change
in cancer treatment. Although traditional chemotherapeutic agents remain the first-line …

Immune checkpoint inhibitors (ICIs), immunomodulatory antibodies that are used to enhance
the immune system, have substantially improved the prognosis of patients with advanced …

Advances in cancer immunity have promoted a major breakthrough in the field of cancer
therapy. This is mainly associated with the successful development of immune checkpoint …